抗CEA预靶向免疫PET在检测复发性转移性甲状腺髓样癌中灵敏度高于DOPA PET/CT
免疫PET总体灵敏度92%,高于18F-DOPA PET/CT的65%;淋巴结、肝和骨转移灵敏度也更高,但肺转移灵敏度较低。
要点
- 免疫PET总体灵敏度92%,高于18F-DOPA PET/CT的65%。
- 免疫PET在淋巴结、肝和骨转移中灵敏度高于CT、18F-DOPA PET/CT或MRI。
- 肺转移免疫PET灵敏度仅29%,CT为100%。
核心结论
- 抗CEA预靶向免疫PET是检测转移性甲状腺髓样癌病灶的有效方法。
- 除肺转移外,免疫PET总体灵敏度高于18F-DOPA PET/CT。
研究设计与样本
- 患者接受68Ga-IMP288经TF2预靶向的免疫PET(注射后1和2小时),并接受颈胸腹盆CT、骨和肝MRI及18F-DOPA PET/CT。
- 金标准为组织学或另一种影像方法或影像随访确认。
主要发现
- 金标准共确认190个病灶:淋巴结89个、肺14个、肝46个、骨37个、其他部位4个(皮下组织、心脏、脑和胰腺)。
- 免疫PET检出210个异常灶,其中174个(83%)被金标准确认为真阳性。
- 免疫PET总体灵敏度92%,18F-DOPA PET/CT为65%。
- 淋巴结灵敏度:免疫PET 98%,CT 83%,18F-DOPA PET/CT 70%;肝灵敏度:免疫PET 98%,CT 87%,18F-DOPA PET/CT 65%,MRI 89%;骨灵敏度:免疫PET 92%,18F-DOPA PET/CT 64%,MRI 86%。
- 肺转移灵敏度:免疫PET 29%,CT 100%,18F-DOPA PET/CT 14%。
关键数值与推荐
- 免疫PET总体灵敏度92%,18F-DOPA PET/CT 65%。
- 淋巴结灵敏度:免疫PET 98%,CT 83%,18F-DOPA PET/CT 70%。
- 肝灵敏度:免疫PET 98%,CT 87%,18F-DOPA PET/CT 65%,MRI 89%。
- 骨灵敏度:免疫PET 92%,18F-DOPA PET/CT 64%,MRI 86%。
- 肺转移灵敏度:免疫PET 29%,CT 100%,18F-DOPA PET/CT 14%。
临床怎么用
- 抗CEA预靶向免疫PET可用于复发性转移性甲状腺髓样癌的病灶检测,尤其对淋巴结、肝和骨转移灵敏度较高。
- 肺转移评估仍应依赖CT,免疫PET对肺转移灵敏度低。
局限性
- 免疫PET检出异常灶中83%被确认为真阳性,存在假阳性可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pretargeting parameters for the use of anti-carcinoembryonic antigen (CEA) bispecific monoclonal antibody TF2 and the 68Ga-labeled IMP288 peptide for immuno-PET have been optimized in a first-in-humans study performed on medullary thyroid carcinoma (MTC) patients (the iPET-MTC study). The aim of this post hoc analysis was to determine the sensitivity of immuno-PET in relapsing MTC patients, in comparison with conventional imaging and 18F-l-dihydroxyphenylalanine (18F-DOPA) PET/CT. Methods: Twenty-five studies were analyzed in 22 patients. All patients underwent immuno-PET 1 and 2 h after 68Ga-IMP288 injection pretargeted by TF2, in addition to neck, thoracic, abdominal, and pelvic CT; bone and liver MRI; and 18F-DOPA PET/CT. The gold standard was histology or confirmation by one other imaging method or by imaging follow-up. Results: In total, 190 lesions were confirmed by the gold standard: 89 in lymph nodes, 14 in lungs, 46 in liver, 37 in bone, and 4 in other sites (subcutaneous tissue, heart, brain, and pancreas). The number of abnormal foci detected by immuno-PET was 210. Among these, 174 (83%) were confirmed as true-positive by the gold standard. Immuno-PET showed a higher overall sensitivity (92%) than 18F-DOPA PET/CT (65%). Regarding metastatic sites, immuno-PET had a higher sensitivity than CT, 18F-DOPA PET/CT, or MRI for lymph nodes (98% vs. 83% for CT and 70% for 18F-DOPA PET/CT), liver (98% vs. 87% for CT, 65% for 18F-DOPA PET/CT, and 89% for MRI), and bone (92% vs. 64% for 18F-DOPA PET/CT and 86% for MRI), whereas sensitivity was lower for lung metastases (29% vs. 100% for CT and 14% for 18F-DOPA PET/CT). Tumor SUVmax at 60 min ranged from 1.2 to 59.0, with intra- and interpatient variability. Conclusion: This post hoc study demonstrates that anti-carcinoembryonic antigen immuno-PET is an effective procedure for detecting metastatic MTC lesions. Immuno-PET showed a higher overall sensitivity than 18F-DOPA PET/CT for disclosing metastases, except for the lung, where CT remains the most effective examination.
引用
- Bodet-Milin C, Faivre-Chauvet A, Carlier T, et al. Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study. J Nucl Med. 2021. PMID: 33547213. doi:10.2967/jnumed.120.252791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。